At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Dose of Neostigminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effectiveness of Neostigmine on the Recovery of Rocuronium-Induced Neuromuscular Blockade: A Comparison Between Partial Dose and TOF Ratio-Based Adjustment Dose
In Brief
A Phase 2 clinical trial evaluating Dose of Neostigmine for Muscle Relaxant and General Anesthesia. Completed, enrolled 66 participants across 1 site.
Detailed Summary
This study aimed to evaluate the effect of Neostigmine partial dose towards neuromuscular blockade of rocuronium
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscle Relaxant, General Anesthesia
CountriesIndonesia
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
Primary CompletionFeb 2017
First PostedFeb 2017
Study CompletionFeb 2017
TodayJul 2026
First PostedFeb 20, 2017
Enrollment StartOct 1, 2016
Primary CompletionFeb 1, 2017
Study CompletionFeb 28, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.4 years ago
Interventions
Dose of Neostigminedrug
Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished